| abstract |
Azaspirodecane Derivatives of Formula I wherein R.sup.1 is n. is C 1-6-10 n-cycloalkyl, optionally substituted with C 3-6 alkyl, or -C (O) OC 1-6 alkyl, decahydronaphthalen-1-yl, decahydronaphthalen-2-yl, indan-1-yl or indan-2-yl, optionally substituted by C.sub.1-6n-alkyl, decahydroazulen-2-yl, bicyclo [6.2.0] dec-9 -yl, acenaphthen-1-yl, 2,3-dihydro-1 H -phenalen-1-yl, 2,3,3a, 4,5,6-hexahydro-1 N -phenalen-1-yl or octahydroinden-1-yl , R.sup.2.n. is hydrogen, C 1-6 1-6 alkyl, = O or phenyl, optionally substituted with C 1-6 -alkyl, halogen, or C 1-6 -alkoxy, A is cyclohexyl or phenyl, X is -CH (OH) -, -C (O) -, -CHR.sup.3-, CR.sup.3, = -O-, -S-, -CH (COOR.sup.4.n) - or -C (COOR.sup.4.n) =, Y is -CH.sub.2-, -CH =, -CH (COO). sup.4.n) -, -C (COOR.sup.4.n) = or -C (CN) -, R.sup.3.n. is hydrogen or C.sub.1-6n.alkoxy, R.sup.4. cycloalkyl, phenyl or benzyl; and either a or b is optionally another bond, in the form of a racemic mixture, and their corresponding enantiomers and pharmaceutically acceptable salts thereof. acid addition salts. Derivatives for treating orphanine-related diseases FQ (OFQ) receptors, including psychiatric, neurological and physiological disorders such as anxiety, stress disorders, depression, trauma, memory loss due to Alzheimer's disease or other dementia, epilepsy and convulsions, acute and / or chronic pain states, withdrawal symptoms in drug abuse, water balance management, excretion of Na.sup. + n., arterial blood pressure disorders and metabolic disorders such as obesity. |